177 lu psma 617 phase 2 study ucla

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
177 lu psma 617 phase 2 study ucla	1.59	0.5	259	25	34
177	1.81	0.7	3578	94	3
lu	0.27	0.8	6175	11	2
psma	0.06	0.2	8781	81	4
617	1.88	1	9362	87	3
phase	1.32	0.2	3135	16	5
2	1.31	1	3786	94	1
study	1.23	0.9	530	51	5
ucla	1.22	0.3	409	47	4

Keyword	CPC	PCC	Volume	Score
177 lu psma 617 phase 2 study ucla	1.78	0.6	2785	41
lu 177 psma 617	1.46	0.6	1339	36
lu 177 psma clinical trials	0.59	0.6	6994	80
lu psma 617 therapy	0.43	0.2	8410	45
lu 177 psma prostate cancer	0.6	0.4	5801	45
lu 177 psma therapy prostate cancer	0.53	0.4	9178	77
lu 177 psma therapy	0.07	0.1	8213	29
lu-177 psma	1.8	0.6	2346	1
lu psma 617 fda approval	0.34	0.7	7122	35
lu 177 psma treatment	1.27	0.7	4154	19
lu 177 psma fda approval	1.36	0.6	8194	80
177 lu-psma-617	1.71	0.8	5234	10
177lu-psma-617 phase 1	0.17	0.5	7200	32
177 lu-psma i&t	1.42	0.7	6973	64
psma-617 lu-177	0.31	0.4	3712	63
177lu-psma 617	1.92	0.1	935	89
177lu-psma-617 breakthrough therapy	0.45	0.7	8431	35
lu177-psma i&t	0.55	0.4	5350	100
177lu-psma	0.39	0.8	8570	32